Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 15

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 15
---
 number of directors. Your proxy cannot be voted for a greater number of persons than the number of nominees named in this proxy statement. Nominees Four Class II directors have been nominated for election at the Annual Meeting, each for a one-year term expiring in 2026. Upon the recommendation of our nominating/corporate governance committee, our board of directors has nominated Rick E Winningham, Jeremy T. Grant, Susannah Gray, and Donal O’Connor, each a current Class II director, for election as Class II directors. The term of office of each person elected as director will continue until such director’s term expires in 2026 and until such director’s successor has been duly elected and qualified or until his or her earlier death, resignation or removal. Information Regarding the Nominees and Other Directors The following is a brief biography of each nominee nominated for election at the Annual Meeting and each director who will continue as a director after the Annual Meeting. Also listed below are the nominees’ and directors’ respective ages as of March 21, 2025. We have determined that each of these director nominees possesses the requisite communication skills, personal integrity, business judgment, ability to make independent analytical inquiries, and willingness to devote adequate time and effort necessary to serve as an effective member of the board of directors. Other specific experiences, qualifications, attributes or skills of nominees that contributed to our board’s conclusion that the nominees should serve as directors are noted below. Nominees for Class II Directors for a Term Expiring in 2026

| Name              | ​ | ​ | Age | ​ | ​ | Principal Occupation and Business Experience                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ​ |
| Rick E Winningham | ​ | ​ |  65 | ​ | ​ | Rick E Winningham has served on the board of directors since July 2013, including as Chairman until October 2024. He has served as our Chief Executive Officer since our spin-off from Innoviva in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001 he served as President, Bristol Myers Squibb Oncology/Immunology/Oncology Therapeutics Network (“OTN”) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for | ​ |

9

TABLE